J&J Secures Extended NICE Approval for Darzalex Following Earlier Refusal

Why It Matters

The expanded NICE endorsement broadens patient access to a more convenient, subcutaneous therapy and strengthens J&J’s position in the UK myeloma market just as its key patents near expiry. It also signals a shift in health‑technology assessment criteria toward clinical benefit despite higher drug costs.

Key Takeaways

• NICE now recommends D‑VRd for transplant‑ineligible frontline myeloma.
• D‑VRd showed 60.9% MRD‑negative rate vs 39.4% for VRd.
• Darzalex offers subcutaneous dosing advantage over Sarclisa’s IV route.
• Recommendation reverses NICE’s earlier refusal for first‑line use.
• J&J faces biosimilar competition as Darzalex patents expire in 2026.

Pulse Analysis

The UK’s National Institute for Health and Care Excellence (NICE) has issued final draft guidance endorsing the Darzalex‑based D‑VRd regimen for patients who cannot undergo stem‑cell transplantation. This move reflects a broader trend among European health authorities to incorporate newer immunotherapies into standard oncology pathways, especially when robust trial data demonstrate clear efficacy gains. By adding D‑VRd to the NHS formulary, clinicians gain a fourth‑line option that aligns with evolving treatment algorithms for multiple myeloma, a disease that affects roughly 8,000 new patients annually in the UK.

Clinical evidence from the Phase III CEPHEUS study underpins NICE’s decision. The trial reported a 60.9% overall minimal residual disease (MRD) negativity rate after a median 58.7‑month follow‑up, markedly higher than the 39.4% observed with the conventional VRd regimen. Beyond the MRD metric, patients on D‑VRd experienced longer progression‑free survival and a more convenient subcutaneous administration, contrasting with Sanofi’s Sarclisa, which requires intravenous infusion. While cost‑effectiveness remains a hurdle for transplant‑eligible cohorts, the agency’s willingness to approve a higher‑priced therapy signals confidence in the long‑term health‑economic benefits of deeper disease control.

For Johnson & Johnson, the NICE endorsement is a strategic win as Darzalex’s primary patents lapse in 2026, opening the door to biosimilar entrants. Securing a broader NHS indication helps lock in market share and generate revenue that can offset upcoming competitive pressure. Moreover, the subcutaneous formulation may serve as a differentiator against biosimilars that often rely on intravenous delivery. The decision also provides a template for future negotiations with other health systems, illustrating how compelling clinical data can outweigh initial cost concerns in high‑value oncology markets.